Immunotherapy
By Dana Taylor
Patients who are receiving immunotherapy should consult with their doctor immediately if and when any side effects occur, because immune-related adverse events may occur during therapy or even after discontinuation of therapy. Read More ›
Enter immunotherapy, stage left. This bright star has gained some traction over the past 2 decades, with the promise of more effective and less hazardous ways to combat cancer. Read More ›
By Dana Taylor
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer. Read More ›
By Dana Taylor
Significant developments in the treatment of lung cancer were reported at the 2017 annual meeting of the European Society for Medical Oncology (ESMO) in Madrid, Spain. Read More ›
An interview with Ross Maclean, MD, PhD, Senior Vice President, Head of Medical at Precision Health Economics, Princeton, NJ, about the importance of personalized medicine in the treatment of cancer. Read More ›
By Nick Bryant
A roundup of 4 leading healthcare professionals offers an optimistic outlook on immunotherapy at the Second International Cancer Immunotherapy Conference, titled “Translating Science into Survival.” Read More ›
Welcome to the first Special Edition of CONQUER: the patient voice, which focuses on immunotherapies in cancer. With the recent explosion of new immunotherapies being approved by the FDA for the treatment of patients with cancer, and their promise for improvements in survival and reduced adverse events, every patient with cancer should become familiar with these new therapies and the hope they bring to patients, survivors, and their family members. Read More ›
Dr. Bruce Gershenhorn examines the hope that immunotherapy brings to patients, explaining the current medications available, side effects, and future of this promising therapeutic option. Read More ›
This article includes immunotherapies approved through May 2017. Read More ›
According to the Cancer Research Institute, only 3% to 6% of eligible patients with cancer participate in clinical trials in the United States. Read the reasons why clinical trials are a great option to consider. Read More ›